Viking Therapeutics (VKTX) — insider trading
Health Care · NASDAQ
Viking Therapeutics (VKTX) has 34 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 15 open-market sales among the most recent 34 (latest 2026-08-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-01 | Kelly-Gemmell Dorothy Elizabeth | Director | Grant / award / vesting (derivative) | 40,800 | — | $0 | Form 4 |
| 2026-08-01 | Kelly-Gemmell Dorothy Elizabeth | Director | Grant / award / vesting | 6,333 | — | $0 | Form 4 |
| 2026-07-29 | Mancini Marianna | Officer (Chief Operating Officer) | Open-market sale | 18,217 | $33.47 | $609.6K | Form 4 |
| 2026-07-29 | ZANTE GREG | Officer (Chief Financial Officer) | Open-market sale | 21,217 | $33.47 | $710.1K | Form 4 |
| 2026-07-29 | Lian Brian | Director, Officer (President & CEO) | Open-market sale | 148,517 | $33.32 | $4.95M | Form 4 |
| 2026-07-28 | Mancini Marianna | Officer (Chief Operating Officer) | Grant / award / vesting | 31,667 | — | $0 | Form 4 |
| 2026-07-28 | ZANTE GREG | Officer (Chief Financial Officer) | Grant / award / vesting | 31,667 | — | $0 | Form 4 |
| 2026-07-28 | Lian Brian | Director, Officer (President & CEO) | Grant / award / vesting | 221,667 | — | $0 | Form 4 |
| 2026-06-01 | Chen Hubert C | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 190,000 | — | $0 | Form 4 |
| 2026-03-10 | Aubuchon Neil William | Officer (Chief Commercial Officer) | Open-market purchase | 4,475 | $33.50 | $149.9K | Form 4 |
| 2026-01-12 | Aubuchon Neil William | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 180,000 | — | $0 | Form 4 |
| 2026-01-05 | Lian Brian | Director, Officer (President & CEO) | Open-market sale | 6,400 | $35.07 | $224.4K | Form 4 |
| 2026-01-05 | Lian Brian | Director, Officer (President & CEO) | Open-market sale | 41,276 | $34.22 | $1.41M | Form 4 |
| 2026-01-05 | Lian Brian | Director, Officer (President & CEO) | Open-market sale | 53,279 | $33.38 | $1.78M | Form 4 |
| 2026-01-05 | Lian Brian | Director, Officer (President & CEO) | Open-market sale | 132,454 | $32.29 | $4.28M | Form 4 |
| 2026-01-05 | Mancini Marianna | Officer (Chief Operating Officer) | Open-market sale | 1,600 | $35.07 | $56.1K | Form 4 |
| 2026-01-05 | Mancini Marianna | Officer (Chief Operating Officer) | Open-market sale | 10,500 | $34.22 | $359.3K | Form 4 |
| 2026-01-05 | Mancini Marianna | Officer (Chief Operating Officer) | Open-market sale | 13,600 | $33.37 | $453.9K | Form 4 |
| 2026-01-05 | Mancini Marianna | Officer (Chief Operating Officer) | Open-market sale | 31,961 | $32.29 | $1.03M | Form 4 |
| 2026-01-05 | ZANTE GREG | Officer (Chief Financial Officer) | Open-market sale | 1,500 | $32.09 | $48.1K | Form 4 |
| 2026-01-05 | ZANTE GREG | Officer (Chief Financial Officer) | Open-market sale | 10,300 | $34.24 | $352.6K | Form 4 |
| 2026-01-05 | ZANTE GREG | Officer (Chief Financial Officer) | Open-market sale | 13,900 | $33.38 | $464.0K | Form 4 |
| 2026-01-05 | ZANTE GREG | Officer (Chief Financial Officer) | Open-market sale | 31,961 | $32.30 | $1.03M | Form 4 |
| 2026-01-02 | SINGLETON J MATTHEW | Director | Grant / award / vesting (derivative) | 20,400 | — | $0 | Form 4 |
| 2026-01-02 | SINGLETON J MATTHEW | Director | Grant / award / vesting | 3,150 | — | $0 | Form 4 |
| 2026-01-02 | Lian Brian | Director, Officer (President & CEO) | Grant / award / vesting (derivative) | 176,300 | — | $0 | Form 4 |
| 2026-01-02 | Lian Brian | Director, Officer (President & CEO) | Grant / award / vesting | 224,080 | — | $0 | Form 4 |
| 2026-01-02 | Lian Brian | Director, Officer (President & CEO) | Grant / award / vesting | 78,400 | — | $0 | Form 4 |
| 2026-01-02 | Mancini Marianna | Officer (Chief Operating Officer) | Grant / award / vesting (derivative) | 91,000 | — | $0 | Form 4 |
| 2026-01-02 | Mancini Marianna | Officer (Chief Operating Officer) | Grant / award / vesting | 32,049 | — | $0 | Form 4 |
| 2026-01-02 | Mancini Marianna | Officer (Chief Operating Officer) | Grant / award / vesting | 41,000 | — | $0 | Form 4 |
| 2026-01-02 | ZANTE GREG | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 91,000 | — | $0 | Form 4 |
| 2026-01-02 | ZANTE GREG | Officer (Chief Financial Officer) | Grant / award / vesting | 32,049 | — | $0 | Form 4 |
| 2026-01-02 | ZANTE GREG | Officer (Chief Financial Officer) | Grant / award / vesting | 41,000 | — | $0 | Form 4 |
Ask the chat about VKTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Viking Therapeutics (VKTX).
Last updated 2026-08-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.